These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38101888)

  • 1. The long road to neuroprotection for Parkinson's disease.
    Trenkwalder C; Mollenhauer B
    Lancet Neurol; 2024 Jan; 23(1):2-3. PubMed ID: 38101888
    [No Abstract]   [Full Text] [Related]  

  • 2. New preclinical model are required to discover neuroprotective compound in Parkinson's disease.
    Segura-Aguilar J
    Pharmacol Res; 2017 May; 119():490. PubMed ID: 27894922
    [No Abstract]   [Full Text] [Related]  

  • 3. Why hasn't neuroprotection worked in Parkinson's disease?
    Kieburtz K; Ravina B
    Nat Clin Pract Neurol; 2007 May; 3(5):240-1. PubMed ID: 17479072
    [No Abstract]   [Full Text] [Related]  

  • 4. GLP-1, Parkinson's Disease, and Neuroprotection.
    Standaert DG
    N Engl J Med; 2024 Apr; 390(13):1233-1234. PubMed ID: 38598580
    [No Abstract]   [Full Text] [Related]  

  • 5. Concerning neuroprotective therapy for Parkinson's disease.
    Uitti RJ; Wszolek ZK
    J Neural Transm Suppl; 2006; (70):433-7. PubMed ID: 17017564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?
    Morgan AH; Rees DJ; Andrews ZB; Davies JS
    Neuropharmacology; 2018 Jul; 136(Pt B):317-326. PubMed ID: 29277488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical aspects of neuroprotection in Parkinson's disease.
    Przuntek H
    J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease.
    Miyazaki I; Asanuma M
    Curr Pharm Des; 2017; 23(33):4936-4947. PubMed ID: 28699520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection in Parkinson's disease: and now for something completely different?
    Lang AE
    Lancet Neurol; 2006 Dec; 5(12):990-1. PubMed ID: 17110271
    [No Abstract]   [Full Text] [Related]  

  • 11. [Neuroprotective effect of baicalein in patients with Parkinson's disease].
    Yu X; He G; Du G
    Zhongguo Zhong Yao Za Zhi; 2012 Feb; 37(4):421-5. PubMed ID: 22667137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection in Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Lancet; 1996 Jan; 347(8995):196. PubMed ID: 8544568
    [No Abstract]   [Full Text] [Related]  

  • 13. Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson's Disease.
    Ghanta MK; Elango P; L V K S B
    Curr Pharm Des; 2020; 26(37):4738-4746. PubMed ID: 32065086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to comment by Juan Segura-Aguilar: New preclinical model are required to discover neuroprotective compound in Parkinson's disease.
    Mattace Raso G; Avagliano C; Calignano A
    Pharmacol Res; 2017 May; 119():491-492. PubMed ID: 27890814
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroprotection in Parkinson's disease: a difficult challenge.
    Stocchi F
    Lancet Neurol; 2015 Aug; 14(8):780-781. PubMed ID: 26116314
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroprotection in Parkinson's disease: a realistic goal?
    Galati S; Di Giovanni G
    CNS Neurosci Ther; 2010 Dec; 16(6):327-9. PubMed ID: 21062424
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroprotection for Parkinson's disease: a call for clinically driven experimental design.
    Bezard E
    Lancet Neurol; 2003 Jul; 2(7):393. PubMed ID: 12849115
    [No Abstract]   [Full Text] [Related]  

  • 18. The six gaps in the search of neuroprotection for Parkinson's disease.
    Espay AJ; Fasano A; Morgante F
    Expert Rev Neurother; 2012 Feb; 12(2):111-3. PubMed ID: 22288665
    [No Abstract]   [Full Text] [Related]  

  • 19. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
    Thibault L; Rascol O; Corvol JC; Ferreira J; Defebvre L; Deplanque D; Bordet R; Moreau C; Devos D
    Mov Disord; 2017 Oct; 32(10):1365-1370. PubMed ID: 28703395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.